Cagrilintide · Research brief

Cagrilintide Cost Per Month Budget — Real Pricing Breakdown

Real Peptides Research TeamEditorial

Updated April 14, 202610 min read

60 WORDS

Short answer

Key takeaways

The cagrilintide cost per month budget includes peptide vials, bacteriostatic water, sterile syringes, alcohol swabs, sharps disposal, cold storage, shipping, and auxiliary anti-nausea medications. Vial-only pricing underestimates true cost by 40–50%.
Research-grade cagrilintide from licensed peptide suppliers costs $320–$450 per 5mg vial with ≥98% purity certification and documented chain of custody, compared to $180–$320 from international vendors with unverified purity claims.
A typical 8-week escalation protocol averaging 1.2mg weekly consumes approximately 9.6mg total peptide, costing $530–$680 per month when reconstitution materials, administration supplies, and auxiliary medications are included.
Dosage protocol structures cost non-linearly. Low-dose weeks (0.3–0.6mg) still require full-vial purchase, creating effective costs of $145–$185 per milligram, while maintenance doses (1.8–2.4mg weekly) drop to $70–$90 per milligram as vial utilization improves.
Multi-vial purchasing from suppliers like Real Peptides reduces per-vial cost by 12–18% and ensures batch consistency across extended protocols, though reconstituted solutions degrade after 28 days regardless of initial purchase volume.

Research conducted at Novo Nordisk's Phase 2 trials demonstrated cagrilintide reduced body weight by up to 10.8% at 26 weeks when combined with semaglutide. Yet the compound remains in investigational status as of 2026, unavailable through FDA-approved retail channels. That forces researchers and clinicians exploring its potential to source cagrilintide through compounding pharmacies and peptide research suppliers, where pricing structures differ radically from conventional pharmaceuticals. We've guided research institutions through peptide procurement protocols for years, and the gap between advertised vial cost and actual monthly budget is where most planning errors occur.

Our team has worked with academic labs and private research groups managing multi-month cagrilintide protocols. The pattern is consistent: initial budget estimates based solely on peptide cost consistently underrun by 35–50%. The full cagrilintide cost per month budget includes reconstitution supplies, sterile storage, administration materials, temperature-controlled shipping, and auxiliary compounds for managing side effects. None of which appear in vial-only pricing.

What is the true monthly cost of running a cagrilintide research protocol?

The cagrilintide cost per month budget ranges between $400 and $900+ depending on compound source (503B compounding pharmacy vs research peptide supplier), dosage protocol (0.3mg weekly escalation vs 2.4mg maintenance), frequency (weekly vs twice-weekly administration), and ancillary costs including bacteriostatic water, sterile syringes, alcohol swabs, sharps containers, and cold chain logistics. A typical 8-week escalation protocol averaging 1.2mg weekly costs approximately $520–$680 per month when sourcing from a licensed peptide research supplier with included reconstitution materials.

The Components Every Cagrilintide Cost Per Month Budget Must Include

Most published estimates cite vial cost and stop there. Creating a 40–50% underestimate that becomes obvious by week two. The actual cagrilintide cost per month budget contains seven distinct line items, each essential to protocol execution.

Peptide vial cost. Research-grade cagrilintide sourced through licensed peptide suppliers typically ranges $280–$450 per 5mg vial depending on batch size, purity certification (≥98% vs ≥99%), and supplier reputation. Compounded versions prepared by 503B facilities run $320–$500 for equivalent milligram quantities. This is the baseline, not the total.

Bacteriostatic water for reconstitution. Lyophilised cagrilintide requires reconstitution with bacteriostatic water (0.9% benzyl alcohol) before administration. A 30ml vial costs $12–$18 and handles 6–8 reconstitutions depending on concentration targets. Standard protocol uses 2ml bacteriostatic water per 5mg vial to achieve 2.5mg/ml concentration. Meaning one 30ml supply covers roughly four monthly cycles.

Sterile administration supplies. Insulin syringes (typically 0.5ml, 29-gauge) cost $0.18–$0.35 each when purchased in boxes of 100. Weekly protocols require 4–5 syringes monthly. Alcohol prep pads run $0.03–$0.05 per unit. Sharps disposal containers approved for biohazard waste cost $8–$15 per 1-quart container and must be replaced every 2–3 months under proper disposal protocols.

Cold chain logistics. Unreconstituted lyophilised cagrilintide must be stored at −20°C; reconstituted solutions require refrigeration at 2–8°C with use within 28 days. Initial shipment from supplier to lab includes insulated packaging and gel packs ($15–$25 shipping surcharge). Labs without −20°C storage capability need benchtop freezers ($180–$400 one-time capital cost).

Auxiliary medications for side effect management. Cagrilintide's amylin-mimetic mechanism produces dose-dependent nausea and delayed gastric emptying in 30–50% of subjects during titration phases. Research protocols commonly include ondansetron (anti-nausea, $0.80–$1.50 per 8mg dose) or metoclopramide (prokinetic agent, $0.40–$0.90 per 10mg dose) as rescue medications. Weekly protocols averaging two doses of ondansetron add $6–$12 monthly.

Lab monitoring and biomarker tracking. Though not a direct peptide cost, comprehensive research protocols include baseline and interval metabolic panels, lipase levels (pancreatitis screening), and thyroid function tests. Commercial lab panels run $85–$180 per draw depending on marker breadth. Monthly monitoring isn't universal but is standard practice in institutional settings.

When summed across a four-week cycle at 1.2mg average weekly dose: peptide vial $350, bacteriostatic water $4 (prorated), syringes and prep materials $6, auxiliary medications $9, cold storage negligible (one-time), shipping $20 = $389 base monthly cost. Add lab monitoring ($140 every 4–8 weeks) and the cagrilintide cost per month budget reaches $530–$680 in practice.

How Dosage Protocol Structures Monthly Peptide Spending

The cagrilintide cost per month budget scales non-linearly with dose because peptide suppliers price by milligram quantity and vial increments don't align neatly with weekly administration schedules. A researcher running 0.6mg weekly (2.4mg monthly) consumes half a 5mg vial per month. But can't purchase half-vials, so the effective cost remains the full vial price of $350–$450.

Phase 2 trials published in The Lancet used escalation protocols starting at 0.3mg weekly and titrating to 2.4mg over 8–12 weeks. Early-phase monthly costs (weeks 1–4 at 0.3–0.6mg weekly) appear lower per milligram consumed but still require full-vial purchase, creating an effective cost of $145–$185 per milligram at low doses. Once protocols reach maintenance doses of 1.8–2.4mg weekly, cost per milligram drops to $70–$90 as vial utilization improves.

Reconstitution concentration impacts waste. Standard practice reconstitutes 5mg cagrilintide in 2ml bacteriostatic water to achieve 2.5mg/ml. A 0.6mg dose requires 0.24ml injection volume. Well within insulin syringe precision range. But protocols using lower concentrations (1mg/ml, requiring 5ml reconstitution volume) reduce per-dose precision and increase waste from syringe dead space. Our experience shows 2.5mg/ml concentration as the optimal balance between dosing accuracy and vial utilization across weekly protocols ranging 0.3mg to 2.4mg.

Multi-vial purchasing reduces per-milligram cost by 12–18%. Research peptide suppliers including Real Peptides offer tiered pricing: single 5mg vial $380, three-vial pack $1,020 ($340/vial), five-vial pack $1,600 ($320/vial). Labs running 12-week protocols consuming 12–15mg total see material savings by purchasing upfront rather than per-month. The trade-off: lyophilised peptides stored at −20°C remain stable for 24+ months, but reconstituted solutions degrade after 28 days. Bulk purchasing only benefits groups with predictable ongoing demand.

Comparison: Cagrilintide Cost Across Supplier Categories

What If: Cagrilintide Cost Per Month Budget Scenarios

What If My Research Protocol Requires Twice-Weekly Dosing Instead of Weekly?

Double your peptide consumption and syringe costs immediately. A twice-weekly 1.2mg protocol (2.4mg weekly total) consumes 9.6mg monthly. Requiring two 5mg vials at $640–$900 for peptide alone. Add doubled syringe costs ($12 monthly vs $6) and reconstitution supplies scale proportionally. Your cagrilintide cost per month budget jumps to $720–$1,050 before lab monitoring. The mechanism driving twice-weekly protocols. Maintaining more stable plasma concentrations of the amylin analog to reduce peak-related nausea. May justify the cost in symptom-sensitive subject populations, but budget planning must account for the doubled peptide burn rate from day one.

What If the Peptide Arrives Warm Due to Shipping Delay?

Reject the shipment and demand replacement. Temperature excursions above 8°C during transit cause irreversible denaturation of the lyophilised protein structure. Cagrilintide's amylin-mimetic peptide backbone degrades rapidly when exposed to heat, and neither visual inspection nor home potency testing can detect partial degradation. Reputable suppliers including Real Peptides include temperature loggers in cold-chain shipments and guarantee replacement for compromised product. Do not reconstitute or administer peptide that experienced temperature deviation. The financial loss of one vial ($350–$450) is negligible compared to protocol failure from underdosed or inactive compound.

What If I Need to Pause My Protocol Mid-Month — Can I Store Reconstituted Cagrilintide Longer?

No. Reconstituted cagrilintide in bacteriostatic water maintains stability for 28 days maximum when refrigerated at 2–8°C. Beyond that window, peptide bond hydrolysis accelerates and bacterial growth risk increases despite the benzyl alcohol preservative. If you must pause a protocol, calculate remaining doses and adjust reconstitution volume to consume the vial within the 28-day stability window. For example, reconstituting 5mg in 1ml instead of 2ml doubles concentration to 5mg/ml, allowing smaller injection volumes and extended vial lifespan per reconstitution batch. Unreconstituted lyophilised peptide stored at −20°C remains stable for 24+ months. The 28-day limit applies only post-reconstitution.

The Unflinching Truth About Cagrilintide Cost Per Month Budget

Here's the honest answer: if you're budgeting solely based on peptide vial cost, you're underestimating by nearly half. And that gap shows up immediately when you place your first order and realize bacteriostatic water, syringes, and sharps containers weren't included. The cagrilintide cost per month budget published on most peptide forums and research planning guides reflects the advertised vial price, not the operational reality of running a sterile administration protocol. We've reviewed hundreds of research budgets in this space, and the consistent error is the same: researchers calculate milligrams needed, multiply by cost per milligram, and stop there.

The bottom line: peptide cost is 60–70% of total monthly spend. The other 30–40%. Reconstitution materials, administration supplies, cold storage, auxiliary medications. Isn't optional. It's the minimum required to execute the protocol safely and effectively. Labs that skip alcohol swabs to save $2 monthly or reuse syringes introduce contamination risk that can invalidate months of data. Peptide research isn't a domain where cutting corners saves money. It's where cutting corners wastes the entire investment.

If your institution or research group is planning a cagrilintide protocol, build your budget with all seven line items from day one: peptide vials, bacteriostatic water, syringes, alcohol prep pads, sharps disposal, shipping and cold storage, and auxiliary anti-nausea support. Add 15% contingency for dose adjustments or protocol extensions. That's the real cagrilintide cost per month budget. Not the number on the vial label.

How Compounding Pharmacy Pricing Differs From Research Supplier Costs

Compounding pharmacies operating under 503B federal registration prepare cagrilintide as a sterile injectable under state pharmacy board oversight. A different regulatory pathway than research peptide suppliers. The practical difference: compounding pharmacies require a valid prescription from a licensed prescriber, bill per prepared dose rather than per milligram of raw peptide, and include reconstitution and sterile filling as part of the service.

A typical 503B-compounded cagrilintide prescription for 2.4mg weekly (four doses monthly) costs $480–$650 and includes pre-filled syringes, alcohol swabs, and sharps container. Eliminating the separate line items researchers must source when purchasing lyophilised peptide. The convenience premium runs 10–20% above DIY reconstitution using research-grade peptide, but removes the reconstitution step entirely and ensures every dose was prepared in a sterile ISO Class 5 cleanroom environment.

For clinical settings where nursing staff administer the peptide or for researchers without access to sterile compounding hoods, 503B compounding represents a turnkey solution. For labs with established peptide handling protocols and sterile technique training, sourcing lyophilised research peptide and reconstituting in-house reduces cost per milligram by 15–25% while maintaining full control over concentration, storage, and administration timing. The cagrilintide cost per month budget calculation depends heavily on whether your operation has the infrastructure and training to handle reconstitution safely. If not, compounding pharmacy pricing becomes the baseline, not the premium.

Our work with research institutions shows the crossover point clearly: groups running single-subject pilots or short-duration feasibility studies benefit from compounding pharmacy convenience despite higher per-dose cost. Labs executing multi-subject protocols over 12+ weeks see material savings by establishing in-house reconstitution workflows and sourcing lyophilised peptide directly. You can explore research-grade cagrilintide and related peptides through trusted suppliers like Real Peptides to compare batch availability and third-party purity certification standards.

The information in this article is for research planning purposes. Peptide sourcing, dosage protocols, and budgeting decisions should align with institutional review board guidelines and applicable research regulations.

If you're mapping the true cost structure for a cagrilintide research protocol, start with the full seven-component budget model outlined above. Not the vial price alone. The researchers who underestimate by 40% in month one are the ones scrambling to secure additional funding in month two when auxiliary costs stack up. Plan for the real number from the start, and your protocol stays on track.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The cagrilintide cost per month budget ranges $400–$900+ depending on peptide source (research supplier vs 503B compounding pharmacy), weekly dosage (0.3mg titration vs 2.4mg maintenance), and whether auxiliary materials are included. A typical 8-week escalation protocol averaging 1.2mg weekly costs approximately $520–$680 monthly when sourcing lyophilised peptide from a licensed research supplier, including bacteriostatic water, sterile syringes, alcohol swabs, sharps disposal, and shipping. Compounded pre-filled syringes from 503B pharmacies run $480–$650 for four weekly 2.4mg doses with all materials included. The peptide vial itself represents 60–70% of total monthly cost — reconstitution supplies, administration materials, and auxiliary anti-nausea medications account for the remaining 30–40%.

Yes — research peptide suppliers offer tiered pricing that reduces per-vial cost by 12–18% when purchasing three or more vials upfront. A single 5mg vial costs $380–$450, while a five-vial pack drops to $320–$340 per vial. The critical constraint: lyophilised cagrilintide stored at −20°C remains stable for 24+ months, but reconstituted solutions degrade after 28 days regardless of initial purchase volume. Bulk purchasing benefits labs running extended protocols with predictable ongoing peptide consumption, but offers no advantage for single-subject pilots or short-duration feasibility studies where total consumption stays below 10mg. Calculate total protocol milligram requirements before committing to multi-vial packs — unused reconstituted peptide past 28 days must be discarded.

Research-grade cagrilintide is sold as lyophilised powder by peptide suppliers for laboratory use, requiring the researcher to reconstitute with bacteriostatic water before administration — purity is verified by third-party HPLC testing (typically ≥98%) with certificates of analysis provided per batch. Compounded cagrilintide is prepared by 503B-registered pharmacies as sterile pre-filled syringes under state pharmacy board oversight, requiring a valid prescription from a licensed prescriber. Both contain the same active amylin-mimetic peptide, but compounded versions include sterile preparation and pre-filling as part of the service, eliminating the reconstitution step. Research-grade peptide costs $320–$450 per 5mg vial; compounded pre-filled syringes cost $480–$650 for four 2.4mg weekly doses. The choice depends on whether your lab has sterile compounding capability and peptide handling protocols — if not, compounded versions represent a turnkey solution despite the 10–20% cost premium.

Peptide suppliers sell cagrilintide in fixed vial sizes (typically 5mg), creating inefficient utilization at low doses. A researcher running 0.6mg weekly consumes 2.4mg monthly — less than half a 5mg vial — but cannot purchase partial vials, so the effective cost remains the full vial price of $350–$450. This creates a cost of $145–$185 per milligram during early titration phases (0.3–0.6mg weekly). Once protocols reach maintenance doses of 1.8–2.4mg weekly, vial utilization improves and cost per milligram drops to $70–$90. The mechanism is packaging, not peptide cost — the same phenomenon occurs with all research peptides sold in discrete vial increments rather than per-milligram custom quantities.

Complete cagrilintide cost per month budgets must include bacteriostatic water for reconstitution ($12–$18 per 30ml vial, covering four monthly cycles), insulin syringes ($0.18–$0.35 each, four to five monthly for weekly protocols), alcohol prep pads ($0.03–$0.05 per unit), sharps disposal containers ($8–$15 per 1-quart container replaced every 2–3 months), cold-chain shipping surcharges ($15–$25 per order), and auxiliary anti-nausea medications like ondansetron ($0.80–$1.50 per 8mg dose, averaging two doses weekly during titration). These items add $80–$140 monthly depending on protocol structure. Labs also commonly include baseline and interval metabolic panels, lipase screening, and thyroid function tests ($85–$180 per draw) every 4–8 weeks. Summed across a four-week cycle, auxiliary costs represent 30–40% of total monthly spend — budgeting for peptide vials alone underestimates true operational cost by approximately 45%.

Reconstituted cagrilintide in bacteriostatic water maintains stability for 28 days maximum when refrigerated at 2–8°C. Beyond that window, peptide bond hydrolysis accelerates and bacterial contamination risk increases despite the benzyl alcohol preservative. Unreconstituted lyophilised cagrilintide stored at −20°C remains stable for 24+ months, so the 28-day limit applies only after mixing with bacteriostatic water. If you must pause a protocol mid-cycle, adjust reconstitution volume to ensure the vial is consumed within 28 days — for example, reconstituting 5mg in 1ml instead of 2ml doubles concentration to 5mg/ml, allowing smaller injection volumes per dose and extending the number of doses per reconstitution batch. Never extend reconstituted peptide storage beyond 28 days regardless of appearance — degradation is not visually detectable and cannot be assessed without HPLC potency testing.

Reject the shipment immediately and contact the supplier for replacement — temperature excursions above 8°C during transit cause irreversible denaturation of cagrilintide’s peptide structure, and neither visual inspection nor home testing can detect partial degradation. Reputable peptide suppliers include temperature data loggers in cold-chain shipments and guarantee replacement for compromised product at no additional cost. Do not reconstitute or administer peptide that experienced temperature deviation — the financial loss of one vial ($350–$450) is negligible compared to protocol failure from underdosed or inactive compound. Suppliers like Real Peptides maintain documented cold-chain logistics with insulated packaging and gel packs designed to maintain −20°C to 2–8°C range for 48–72 hours in transit.

No — reusing syringes introduces bacterial contamination risk, needle dulling that increases injection pain and tissue trauma, and potential peptide degradation from residual solution exposure to air. Insulin syringes cost $0.18–$0.35 each when purchased in 100-unit boxes, adding only $6–$8 monthly to a weekly protocol — the cost savings from reuse are negligible, while the contamination risk can invalidate months of research data or cause injection-site infections. Sterile technique is non-negotiable in peptide administration protocols. Every injection requires a new sterile syringe, fresh alcohol prep pad, and proper sharps disposal. Labs attempting to reduce costs by reusing administration supplies introduce variables that confound results and violate basic research safety standards.

Cagrilintide remains investigational as of 2026, available only through research suppliers and compounding pharmacies, while semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are FDA-approved with standardized retail pricing. Research-grade cagrilintide costs $320–$450 per 5mg vial; research-grade semaglutide costs $180–$280 per 5mg; research-grade tirzepatide costs $240–$360 per 10mg. On a per-milligram basis at maintenance doses, cagrilintide runs approximately $70–$90/mg, semaglutide $50–$70/mg, and tirzepatide $24–$36/mg. The cost difference reflects supply chain maturity and market competition — semaglutide and tirzepatide have established compounding infrastructure and multiple supplier sources, while cagrilintide sourcing remains limited to specialized peptide research vendors. Combination protocols using cagrilintide plus semaglutide (as tested in Novo Nordisk Phase 2 trials) double monthly peptide costs but demonstrated superior weight reduction (10.8% at 26 weeks) compared to either agent alone.

It depends on the supplier type. Research peptide suppliers sell lyophilised cagrilintide for laboratory and research use without requiring a prescription — the peptide is sold under the understanding it will be used for scientific investigation, not human clinical treatment. Compounding pharmacies operating under 503B federal registration require a valid prescription from a licensed prescriber before preparing and dispensing sterile cagrilintide injections. The regulatory distinction: research peptides are sold as laboratory reagents; compounded medications are prepared as patient-specific prescriptions under pharmacy board oversight. Labs affiliated with academic institutions or private research organizations typically source through peptide suppliers; clinical settings under prescriber supervision source through compounding pharmacies. Both pathways are legal, but the procurement process and documentation requirements differ based on intended use classification.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA